WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1998051217) VACCINE AGAINST LIPOPOLYSACCHARIDE CORE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1998/051217    International Application No.:    PCT/US1998/009988
Publication Date: 19.11.1998 International Filing Date: 15.05.1998
Chapter 2 Demand Filed:    10.12.1998    
IPC:
A61K 39/108 (2006.01), A61K 39/112 (2006.01)
Applicants: MEDICAL DEFENSE TECHNOLOGIES, LLC [US/US]; 175 East 96th Street #4C, New York, NY 10128 (US) (For All Designated States Except US).
BENNETT-GUERRERO, Elliott [US/US]; (US) (For US Only).
BARCLAY, George, Robin [GB/GB]; (GB) (For US Only).
POXTON, Ian, Raymond [GB/GB]; (GB) (For US Only).
MCINTOSH, Thomas, James [US/US]; (US) (For US Only).
SNYDER, David, Scott [US/US]; (US) (For US Only)
Inventors: BENNETT-GUERRERO, Elliott; (US).
BARCLAY, George, Robin; (GB).
POXTON, Ian, Raymond; (GB).
MCINTOSH, Thomas, James; (US).
SNYDER, David, Scott; (US)
Agent: FREEMAN, John, W.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US)
Priority Data:
60/046,680 16.05.1997 US
Title (EN) VACCINE AGAINST LIPOPOLYSACCHARIDE CORE
(FR) VACCIN DIRIGE CONTRE LES NOYAUX DE LIPOPOLYSACCHARIDES
Abstract: front page image
(EN)Complete core LPS (lacking O-polysaccharide side chains) from Gram-negative bacteria are incorporated into a vaccine typically in liposomes. The complete core of $i(E. coli) K 12 is particularly useful. Upon administration to a mammal the vaccine stimulates synthesis of antibodies which are cross-protective against smooth and rough forms of LPS from at least two different Gram-negative bacterial strains having different core structures.
(FR)Selon cette invention, on incorpore à un vaccin se présentant généralement sous forme de liposomes, des lipopolysaccharides (LPS) à noyau complet (dépourvus de chaînes latérales de O-polysaccharide) provenant de bactéries Gram négatif. Le noyau complet de $i(E.coli) K12 s'avère particulièrement utile. Lorsqu'on l'administre à un mammifère, ce vaccin stimule la synthèse d'anticorps qui assurent une protection croisée contre les formes lisses et rugueuses de LPS, à partir d'au moins deux souches bactériennes Gram négatif dotées de structures de noyaux différentes.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)